Abstract
Besides cytotoxic and targeted therapy, immunotherapy has become another alternative in the treatment of advanced lung cancer. Pembrolizumab is a humanized IgG4 monoclonal antibody against PD-1, which was approved by the FDA and EMA for the treatment of locally advanced or metastatic non-small-cell lung cancer in patients whose tumours express PD-L1 and who have been treated with at least one chemotherapy.
Patients with positive tumour EGFR or ALK mutations must be treated before treatment with pembrolizumab with approved therapies. The safety and efficacy of pembrolizumab was evaluated in a phase II/III KEYNOTE-010.